Our Product – UbiHealth

Our first product will enable at-home detection of SARS-CoV-2 RNA and multiplexed identification of Variants-of-Concern (VOC) from a self-collected saliva sample with the sensitivity and specificity of a laboratory test.

Our technology enables digital platforms to enhance engagement with consumers by giving them direct access to critical biological information in real time.

Our first product will enable at-home detection of SARS-CoV-2 RNA and multiplexed identification of Variants-of-Concern (VOC) from a self-collected 2mL saliva sample achieving state-of-the-art 1000 cp/mL limit of detection. Eight optimised PNA probe pairs target RdRp, Orf1a and Spike RBD regions and mutations, providing detection and genotyping identification of selected and relevant current VOCs. At-home molecular testing and detection of SARS-CoV-2 RNA from a saliva sample, and identification of VOCs, if present, will be a significant innovation in point of care testing.

The safe sealed test cartridge will eliminate the risks due to sample handling and shipping to laboratories. It addresses the post-pandemic ongoing unmet needs of a home SARS-CoV-2 viral RNA test, and real-time field surveillance.